The Aenova Group, one of the leading companies in the global pharmaceutical and health care industry, is in the process of taking over the Temmler Group. An agreement was reached with the previous owners. The purchase price will remain confidential. The acquisition is conditional on the approval of the relevant competition authorities and is likely to become legally binding at the end of 2012.
The Temmler Group is a well-known international pharmaceutical company, which, as a result of acquisitions in recent years, has established a strong market position as full-service-provider for pharmaceutical contract manufacturing. The Group has seven production sites in Germany, Switzerland, Italy and Ireland employing around 1,000 people and a turnover of around EUR 170 million.
The Aenova Group, a leading provider of services for the development, manufacturing and commercialisation of solid dosage forms, already has a wide range of customers in the pharmaceutical and healthcare industries. “The acquisition of the Temmler Group allows us to extend our position as European market leader. The portfolios of the two companies complement one another perfectly, as the Temmler Group produces dosage forms such as salves, gels and drops and is involved in new service segments, including the manufacture of clinical trial materials, distribution logistics and licensing,” explains Heiner Hoppmann, CEO of the Aenova Group.
Dr. Werner Schneider, CEO of the Temmler Group, also takes a positive view of the future collaboration: “The planned integration into the Group gives Temmler an excellent perspective for the future and for the ongoing development of the business.”
The equity for the transaction is being provided by funds advised by BC Partners, which acquired Aenova in August 2012.
With an annual turnover of around EUR 280 million, the Aenova Group is one of the world’s leading companies in the pharmaceutical and health care industries. As a result of its high standards of quality, innovative technologies and clear focus on the future, Aenova has become Europe’s leading provider of development, manufacturing and marketing services for medicines and dietary supplements. Its portfolio consists of solid dosage forms, such as soft gelatin capsules, hard capsules, conventional tablets, film-coated tablets, dragées and effervescent tablets. The company’s headquarters are located in Pähl near Munich. It has seven production sites in five countries (Germany, Switzerland, France, Romania and the USA) and employs a total of around 1,600 people.
About the Temmler Group
The Temmler Group is a pharmaceutical service organisation which has its headquarters in Marburg in Germany. The company was founded in 1917. Today the Temmler Group is one of Europe’s leading full-service providers in pharmaceutical contract manufacturing. It has around 1,000 employees at seven production sites in Germany, Ireland, Italy and Switzerland. It offers the entire range of contract manufacturing services for solid, semi-solid and liquid dosage forms. It also develops and sells its own pharmaceutical products.